Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis.

Cheema, Huzaifa A; Jafar, Uzair; Sohail, Aruba; Shahid, Abia; Sahra, Syeda; Ehsan, Muhammad; Athar, Farwa; Shah, Jaffer; Sah, Ranjit

Cheema, Huzaifa A; Jafar, Uzair; Sohail, Aruba; Shahid, Abia; Sahra, Syeda; Ehsan, Muhammad; Athar, Farwa; Shah, Jaffer; Sah, Ranjit.

Cheema HA; Division of Infectious Diseases, Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Jafar U; Division of Infectious Diseases, Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Sohail A; Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Shahid A; Division of Infectious Diseases, Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Sahra S; Department of Infectious Diseases, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Ehsan M; Division of Infectious Diseases, Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Athar F; Division of Infectious Diseases, Department of Medicine, King Edward Medical University, Lahore, Pakistan.
Shah J; New York State Department of Health, Albany, New York, USA.
Sah R; Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal.

J Med Virol ; 95(2): e28471, 2023 02.

Article in English | MEDLINE | ID: covidwho-2173233

Subject(s)

COVID-19; Ritonavir; Humans; Classification; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ritonavir / COVID-19 Type of study: Reviews / Systematic review/Meta Analysis Limits: Humans Language: English Journal: J Med Virol Year: 2023 Document Type: Article Affiliation country: Jmv.28471

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google